Mutations of the gene for the aryl hydrocarbon receptor-interacting protein in pituitary adenomas

Hormone Research

Volumn 71, Issue 3, 2009, Pages 132-141

  Cazabat, Laure ^a,b,e,f   Guillaud Bataille, Marine ^b   Bertherat, Jérôme ^a,b,e,f   Raffin Sanson, Marie Laure ^a,c,d,e,f  

^a INSERM   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c HÔPITAL AMBROISE PARÉ   (France)

^d LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^e INSTITUT COCHIN   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Acromegaly; Aryl hydrocarbon receptor interacting protein gene; Familial isolated pituitary adenomas; Isolated familial somatotropinomas; Pituitary adenoma

Indexed keywords

ARYL HYDROCARBON RECEPTOR INTERACTING PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ACROMEGALY; AGE DISTRIBUTION; CANCER GENETICS; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CLINICAL FEATURE; FAMILIAL CANCER; FRAMESHIFT MUTATION; GENE DELETION; GENE FUNCTION; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HORMONE RELEASE; HUMAN; HYPOPHYSIS; HYPOPHYSIS ADENOMA; MISSENSE MUTATION; NONSENSE MUTATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RNA SPLICING; SEX DIFFERENCE; SHORT SURVEY;

EID: 59749104638     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000197869     Document Type: Short Survey

References (45)

1. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE: The prevalence of pituitary adenomas: a systematic review. Cancer 2004;101:613-619.
2. Hall WA, Luciano MG, Doppman JL, Patronas NJ, Oldfield EH: Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 1994;120:817-820.
3. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A: High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006;91:4769-4775.
4. Verges B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, Cougard P, Chambe B, Montvernay C, Calender A: Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 2002;87:457-465.
5. Bertherat J: Carney complex (CNC). Orphanet J Rare Dis 2006;1:21.
6. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Crabtree JS, Wang Y, Roe BA, Weisemann J, Boguski MS, Agarwal SK, Kester MB, Kim YS, Heppner C, Dong Q, Spiegel AM, Burns AL, Marx SJ: Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997;276:404-407.
7. Daly AF, Jaffrain-Rea ML, Beckers A: Clinical and genetic features of familial pituitary adenomas. Horm Metab Res 2005;37:347-354.
8. Beckers A, Daly AF: The clinical, pathological, and genetic features of familial isolated pituitary adenomas. Eur J Endocrinol 2007;157:371-382.
9. Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen K, Ebeling TM, Salmela PI, Paschke R, Gundogdu S, De Menis E, Makinen MJ, Launonen V, Karhu A, Aaltonen LA: Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006;312:1228-1230.
10. Barlier A, Vanbellinghen JF, Daly AF, Silvy M, Jaffrain-Rea ML, Trouillas J, Tamagno G, Cazabat L, Bours V, Brue T, Enjalbert A, Beckers A: Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. J Clin Endocrinol Metab 2007;92:1952-1955.
11. Cazabat L, Libe R, Perlemoine K, Rene-Corail F, Burnichon N, Gimenez-Roqueplo AP, Dupasquier-Fediaevsky L, Bertagna X, Clauser E, Chanson P, Bertherat J, Raffin-Sanson ML: Germline-inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. Eur J Endocrinol 2007;157:1-8.
12. Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA, Guitelman MA, Murat A, Emy P, Gimenez-Roqueplo AP, Tamburrano G, Raverot G, Barlier A, De Herder W, Penfornis A, Ciccarelli E, Estour B, Lecomte P, Gatta B, Chabre O, Sabate MI, Bertagna X, Garcia Basavilbaso N, Stalldecker G, Colao A, Ferolla P, Wemeau JL, Caron P, Sadoul JL, Oneto A, Archambeaud F, Calender A, Sinilnikova O, Montanana CF, Cavagnini F, Hana V, Solano A, Delettieres D, Luccio-Camelo DC, Basso A, Rohmer V, Brue T, Bours V, Teh BT, Beckers A: Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab 2007;92:1891-1896.
13. Georgitsi M, Raitila A, Karhu A, Tuppurainen K, Makinen MJ, Vierimaa O, Paschke R, Saeger W, van der Luijt RB, Sane T, Robledo M, De Menis E, Weil RJ, Wasik A, Zielinski G, Lucewicz O, Lubinski J, Launonen V, Vahteristo P, Aaltonen LA: Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proc Natl Acad Sci USA 2007;104:4101-4105.
14. Iwata T, Yamada S, Mizusawa N, Golam HM, Sano T, Yoshimoto K: The aryl hydrocarbon receptor-interacting protein gene is rarely mutated in sporadic GH-secreting adenomas. Clin Endocrinol (Oxf) 2007;66:499-502.
15. Naves LA, Daly AF, Vanbellinghen JF, Casulari LA, Spilioti C, Magalhaes AV, Azevedo MF, Giacomini LA, Nascimento PP, Nunes RO, Rosa JW, Jaffrain-Rea ML, Bours V, Beckers A: Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene. Eur J Endocrinol 2007;157:383-391.
16. Raitila A, Georgitsi M, Karhu A, Tuppurainen K, Makinen MJ, Birkenkamp-Demtroder K, Salmenkivi K, Orntoft TF, Arola J, Launonen V, Vahteristo P, Aaltonen LA: No evidence of somatic aryl hydrocarbon receptor interacting protein mutations in sporadic endocrine neoplasia. Endocr Relat Cancer 2007;14:901-906.
17. Toledo RA, Lourenco DM Jr, Liberman B, Cunha-Neto MB, Cavalcanti MG, Moyses CB, Toledo SP, Dahia PL: Germline mutation in the aryl hydrocarbon receptor interacting protein gene in familial somatotropinoma. J Clin Endocrinol Metab 2007;92:1934-1937.
18. Georgitsi M, Raitila A, Karhu A, van der Luijt RB, Aalfs CM, Sane T, Vierimaa O, Makinen MJ, Tuppurainen K, Paschke R, Gimm O, Koch CA, Gundogdu S, Lucassen A, Tischkowitz M, Izatt L, Aylwin S, Bano G, Hodgson S, De Menis E, Launonen V, Vahteristo P, Aaltonen LA: Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab 2007;92:3321-3325.
19. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Hofler H, Fend F, Graw J, Atkinson MJ: Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA 2006;103:15558-15563.
20. Ozawa A, Agarwal SK, Mateo CM, Burns AL, Rice TS, Kennedy PA, Quigley CM, Simonds WF, Weinstein LS, Chandrasekharappa SC, Collins FS, Spiegel AM, Marx SJ: The parathyroid/pituitary variant of multiple endocrine neoplasia type 1 usually has causes other than p27Kip1 mutations. J Clin Endocrinol Metab 2007;92:1948-1951.
21. Akintoye SO, Chebli C, Booher S, Feuillan P, Kushner H, Leroith D, Cherman N, Bianco P, Wientroub S, Robey PG, Collins MT: Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome. J Clin Endocrinol Metab 2002;87:5104-5112.
22. Vallar L, Spada A, Giannattasio G: Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 1987;330:566-568.
23. Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS, Cho-Chung YS, Stratakis CA: Mutations of the gene encoding the protein kinase A type I-α regulatory subunit in patients with the Carney complex. Nat Genet 2000;26:89-92.
24. Kovacs K, Horvath E, Thorner MO, Rogol AD: Mammosomatotroph hyperplasia associated with acromegaly and hyperprolactinemia in a patient with the McCune-Albright syndrome. A histologic, immunocytologic and ultrastructural study of the surgically-removed adenohypophysis. Virchows Arch A Pathol Anat Histopathol 1984;403:77-86.
25. Pack SD, Kirschner LS, Pak E, Zhuang Z, Carney JA, Stratakis CA: Genetic and histologic studies of somatomammotropic pituitary tumors in patients with the 'complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas' (Carney complex). J Clin Endocrinol Metab 2000;85:3860-3865.
26. Sandrini F, Kirschner LS, Bei T, Farmakidis C, Yasufuku-Takano J, Takano K, Prezant TR, Marx SJ, Farrell WE, Clayton RN, Groussin L, Bertherat J, Stratakis CA: PRKAR1A, one of the Carney complex genes, and its locus (17q22-24) are rarely altered in pituitary tumours outside the Carney complex. J Med Genet 2002;39:e78.
27. Zhuang Z, Ezzat SZ, Vortmeyer AO, Weil R, Oldfield EH, Park WS, Pack S, Huang S, Agarwal SK, Guru SC, Manickam P, Debelenko LV, Kester MB, Olufemi SE, Heppner C, Crabtree JS, Burns AL, Spiegel AM, Marx SJ, Chandrasekharappa SC, Collins FS, Emmert-Buck MR, Liotta LA, Asa SL, Lubensky IA: Mutations of the MEN1 tumor suppressor gene in pituitary tumors. Cancer Res 1997;57:5446-5451.
28. Carver LA, Bradfield CA: Ligand-dependent interaction of the aryl hydrocarbon receptor with a novel immunophilin homolog in vivo. J Biol Chem 1997;272:11452-11456.
29. Kuzhandaivelu N, Cong YS, Inouye C, Yang WM, Seto E: XAP2, a novel hepatitis B virus X-associated protein that inhibits X transactivation. Nucleic Acids Res 1996;24:4741-4750.
30. Sumanasekera WK, Tien ES, Turpey R, Vanden Heuvel JP, Perdew GH: Evidence that peroxisome proliferator-activated receptor alpha is complexed with the 90-kDa heat-shock protein and the hepatitis virus B X-associated protein 2. J Biol Chem 2003;278:4467-4473.
31. Carver LA, LaPres JJ, Jain S, Dunham EE, Bradfield CA: Characterization of the Ah receptor-associated protein, ARA9. J Biol Chem 1998;273:33580-33587.
32. Bell DR, Poland A: Binding of aryl hydrocarbon receptor (AhR) to AhR-interacting protein. The role of hsp90. J Biol Chem 2000;275:36407-36414.
33. Bolger GB, Peden AH, Steele MR, MacKenzie C, McEwan DG, Wallace DA, Huston E, Baillie GS, Houslay MD: Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. J Biol Chem 2003;278:33351-33363.
34. De Oliveira SK, Hoffmeister M, Gambaryan S, Muller-Esterl W, Guimaraes JA, Smolenski AP: Phosphodiesterase 2A forms a complex with the co-chaperone XAP2 and regulates nuclear translocation of the aryl hydrocarbon receptor. J Biol Chem 2007;282:13656-13663.
35. Oesch-Bartlomowicz B, Huelster A, Wiss O, Antoniou-Lipfert P, Dietrich C, Arand M, Weiss C, Bockamp E, Oesch F: Aryl hydrocarbon receptor activation by cAMP vs. dioxin: divergent signaling pathways. Proc Natl Acad Sci USA 2005;102:9218-9223.
36. Kang BH, Altieri DC: Regulation of survivin stability by the aryl hydrocarbon receptor-interacting protein. J Biol Chem 2006;281:24721-24727.
37. Lees MJ, Peet DJ, Whitelaw ML: Defining the role for XAP2 in stabilization of the dioxin receptor. J Biol Chem 2003;278:35878-35888.
38. Lin BC, Sullivan R, Lee Y, Moran S, Glover E, Bradfield CA: Deletion of the aryl hydrocarbon receptor-associated protein 9 leads to cardiac malformation and embryonic lethality. J Biol Chem 2007;282:35924-35932.
39. Soares BS, Eguchi K, Frohman LA: Tumor deletion mapping on chromosome 11q13 in eight families with isolated familial somatotropinoma and in 15 sporadic somatotropinomas. J Clin Endocrinol Metab 2005;90:6580-6587.
40. Aaltonen LA: Aryl hydrocarbon receptor-interacting protein and acromegaly. Horm Res 2007;68(suppl 5):127-131.
41. Georgitsi M, Karhu A, Winqvist R, Visakorpi T, Waltering K, Vahteristo P, Launonen V, Aaltonen LA: Mutation analysis of aryl hydrocarbon receptor interacting protein (AIP) gene in colorectal, breast, and prostate cancers. Br J Cancer 2007;96:352-356.
42. Daly AF, Jaffrain-Rea ML, Ciccarelli A, Valdes-Socin H, Rohmer V, Tamburrano G, Borson-Chazot C, Estour B, Ciccarelli E, Brue T, Ferolla P, Emy P, Colao A, De Menis E, Lecomte P, Penfornis F, Delemer B, Bertherat J, Wemeau JL, De Herder W, Archambeaud F, Stevenaert A, Calender A, Murat A, Cavagnini F, Beckers A: Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab 2006;91:3316-3323.
43. Digiovanni R, Serra S, Ezzat S, Asa SL: AIP mutations are not identified in patients with sporadic pituitary adenomas. Endocr Pathol 2007;18:76-78.
44. Yu R, Bonert V, Saporta I, Raffel LJ, Melmed S: Aryl hydrocarbon receptor interacting protein variants in sporadic pituitary adenomas. J Clin Endocrinol Metab 2006;91:5126-5129.
45. Tamburrano G, Jaffrain-Rea ML, Grossi A, Lise A, Bulletta C: Familial acromegaly. Apropos of a case. Review of the literature (in French). Ann Endocrinol (Paris) 1992;53:201-207.